Literature DB >> 8226146

The influence of field size and other treatment factors on pulmonary toxicity following hyperfractionated irradiation for inoperable non-small cell lung cancer (NSCLC)--analysis of a Radiation Therapy Oncology Group (RTOG) protocol.

R W Byhardt1, L Martin, T F Pajak, K H Shin, B Emami, J D Cox.   

Abstract

PURPOSE: The risk of pulmonary toxicity, observed in an Radiation Therapy Oncology Group Phase I/II randomized dose escalation trial of hyperfractionated irradiation for nonsmall cell lung cancer, was analyzed with regard to custom vs. hand blocking and compliance to protocol specified treatment field parameters.
MATERIALS AND METHODS: There were 832 evaluable cases analyzed. The protocol required field margins 2 cm beyond primary tumor and involved nodes. In 674, the field margins were considered "per protocol" or as having minor protocol variations. In 94, margins exceeded protocol specification ("excessive margin" group). In this group, the area (cm2) of the effective (blocked) field and the portion including lung was measured from simulator films with a computer scanning device. Based on size and location of the primary and nodal disease, "per protocol" fields were constructed and the area (cm2) of lung included beyond these margins was estimated. Patients from both groups who received less than 30 Gy to normal lung were excluded from analysis of pulmonary toxicity.
RESULTS: Grade 1 acute lung toxicity was higher (p = .009) in the "excessive margin" group compared to the "per protocol" group, whereas late lung toxicity was not significantly different (p = .94). The risk of Grade 2 or greater acute toxicity increased as area of excess irradiated lung increased. Overall lung toxicity, defined as the greater of either acute or late toxicity, was evaluated by multivariate analysis, in relation to assigned dose, effective treated field area, and type of shielding. Overall maximum lung toxicity (> or = Grade 2) was significantly greater in the "excessive margin" group, when lung treated beyond protocol margins exceeded an area of 35 cm2, than in the "per protocol" group, but only when the effective treated field size was > or = 180 cm2 (68% vs. 37%; p = .02). This effect was independent of assigned total dose or type of shielding.
CONCLUSION: For nonsmall cell lung cancer treated with hyperfractionated irradiation, the risk of overall pulmonary toxicity was increased for patients treated with field sizes in excess of protocol specified margins of tumor coverage in comparison to patients treated with protocol specified margins. This effect was seen only when the area of lung treated beyond protocol margins exceeded 35 cm2 and when the overall field size was below 180 cm2.

Entities:  

Mesh:

Year:  1993        PMID: 8226146     DOI: 10.1016/0360-3016(93)90377-8

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  7 in total

1.  A phase I study of concurrent chemotherapy (paclitaxel and carboplatin) and thoracic radiotherapy with swallowed manganese superoxide dismutase plasmid liposome protection in patients with locally advanced stage III non-small-cell lung cancer.

Authors:  Ahmad A Tarhini; Chandra P Belani; James D Luketich; Athanassios Argiris; Suresh S Ramalingam; William Gooding; Arjun Pennathur; Daniel Petro; Kevin Kane; Denny Liggitt; Tony Championsmith; Xichen Zhang; Michael W Epperly; Joel S Greenberger
Journal:  Hum Gene Ther       Date:  2011-02-02       Impact factor: 5.695

Review 2.  Survivorship in Non-Small Cell Lung Cancer: Challenges Faced and Steps Forward.

Authors:  Namrata Vijayvergia; Prashant C Shah; Crystal S Denlinger
Journal:  J Natl Compr Canc Netw       Date:  2015-09       Impact factor: 11.908

3.  Role of gross tumor volume on outcome and of dose parameters on toxicity of patients undergoing chemoradiotherapy for locally advanced non-small cell lung cancer.

Authors:  Luigi De Petris; Ingmar Lax; Florin Sirzén; Signe Friesland
Journal:  Med Oncol       Date:  2005       Impact factor: 3.064

4.  [Pneumonitis after radiotherapy of bronchial carcinoma: incidence and influencing factors].

Authors:  P Schraube; R Schell; M Wannenmacher; P Drings; M Flentje
Journal:  Strahlenther Onkol       Date:  1997-07       Impact factor: 3.621

5.  Integration of irinotecan and cisplatin with early concurrent conventional radiotherapy for limited-disease SCLC (LD-SCLC).

Authors:  Sherif Abdelwahab; Hatem Abdulla; Ali Azmy; Ahmed Abdelfatah; Hany Abdel-Aziz; Maha Margerges; Atef Riad; Vinay Sharma; Ibrahim Dwedar
Journal:  Int J Clin Oncol       Date:  2009-07-11       Impact factor: 3.402

6.  A case of radiotherapy for an advanced bronchial carcinoma patient with implanted cardiac rhythm machines as well as heart assist device.

Authors:  Sergiu Scobioala; Iris Ernst; Christos Moustakis; Uwe Haverkamp; Sven Martens; Hans Theodor Eich
Journal:  Radiat Oncol       Date:  2015-04-07       Impact factor: 3.481

7.  Three-Dimensional Conformal Radiotherapy-Based or Intensity-Modulated Radiotherapy-Based Concurrent Chemoradiotherapy in Patients with Thoracic Esophageal Squamous Cell Carcinoma.

Authors:  Wei-Cheng Lin; Chia-Lun Chang; Han-Lin Hsu; Kevin Sheng-Po Yuan; Alexander T H Wu; Szu-Yuan Wu
Journal:  Cancers (Basel)       Date:  2019-10-10       Impact factor: 6.639

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.